RHC.AX
RHC.AX has a debt-to-equity ratio of 2.41, indicating a significant reliance on debt financing, which is higher than the typical industry median for healthcare facilities and services. The company's liquidity position is characterized as medium, with a current ratio of 0.9, suggesting that it may struggle to meet short-term obligations without additional financing. Profitability metrics for RHC.AX are weak, with a return on equity of 0.48% and a return on assets of 0.11%. These figures are below the industry benchmarks, indicating that the company is not effectively utilizing its equity and assets to generate returns. The net income of 24 million AUD is also significantly lower than the operating income of 707.7 million AUD, highlighting the presence of substantial non-operating expenses or losses. The company's revenue is primarily concentrated in its domestic market, with no significant international operations disclosed. This concentration increases the company's exposure to local economic conditions and regulatory changes. The lack of geographic diversification is a notable risk factor, especially in a sector that is highly regulated and sensitive to policy changes. RHC.AX's growth trajectory is modest, with the company's revenue in the latest period standing at 1.78 billion AUD. While the company has a positive operating cash flow of 1.48 billion AUD, the free cash flow is only 217.2 million AUD, which is insufficient to cover the capital expenditures of 776.6 million AUD. This suggests that the company may need to rely on external financing to fund its capital needs, which could increase its debt burden and financial risk. The risk assessment for RHC.AX indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after accounting for total debt, which could limit its ability to respond to unexpected financial needs. The low dilution risk is attributed to the absence of significant dilution sources in the recent filings and the stable number of shares outstanding. Recent events and filings for RHC.AX include the latest financial results, which show a decline in net income despite a relatively stable revenue. The company's management has not disclosed any major strategic initiatives or new product launches in the recent transcripts, which may indicate a lack of growth drivers. The analyst estimates suggest a mixed outlook, with a mean price target of 42.60 AUD and a median price target of 43.15 AUD, reflecting cautious optimism among analysts.
Business. RHC.AX operates in the healthcare sector, providing pharmaceutical products and services, primarily through its operations in Australia.
Classification. RHC.AX is classified under the Healthcare Facilities & Services industry within the Healthcare Services & Equipment business sector, with a classification confidence of 0.92.
- RHC.AX has a high debt-to-equity ratio of 2.41, indicating a significant reliance on debt financing.
- The company's profitability metrics, such as return on equity and return on assets, are below industry benchmarks.
- RHC.AX's revenue is primarily concentrated in its domestic market, increasing its exposure to local economic and regulatory conditions.
- The company's free cash flow is insufficient to cover its capital expenditures, suggesting a need for external financing.
- Analysts have a mixed outlook on RHC.AX, with a mean price target of 42.60 AUD and a median price target of 43.15 AUD.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.